TIL Desk/Business/New Delhi-Pharmaceutical giant Pfizer plans to introduce more drugs from its global portfolio in India, including injectables from the stable of Hospira which it had acquired last year. Although the company sells most of its top 20 global products in India, it is looking to bring in a couple of drugs, the patents of which have expired, to the domestic market.
“Except for a couple of CNS (central nervous system) products and one pain product, we are not really missing a major portfolio. We are looking at couple of global products, though they have gone all off LOE (loss of exclusivity) to reintroduce them into India, we are also looking at that aspect of this juncture,” Pfizer India Managing Director S Sridhar told.
Out of all the top 20 global big products that Pfizer has, other than Lipitor and another two or three very small products, the company has all the portfolio in India, either in the name as such or in the local name, he said.
